No abstract

Spirulina is a micro algae used for thousands of years due to its healing properties. We supplemented children suffering from sickle cell anemia in order to appreciate its impact on the anthropometrical and clinical parameters. It consisted of a randomized clinical double blind test which was carried during a period of 9 months. The study concerned 53 homozygotes children suffering from sickle cell anemia aged 6 months to 15 years. Also, they were visiting the National Hospital of Niamey for follow up. One group (28 children) received 5 g of spirulina daily, and the other group (25 children) received placebo. The aspects studied were: the number of hospitalizations and transfusions, the vaso-occlusive crisis, the body mass index, and the splenomegalia. We found that 84.90% of patients were hospitalized at least once and 45.3% of them have already been transfused. The average number of crisis has greatly decreased in the spirulina group from 2.75 before the study to 1.18 at the end of the study. This, thus, was observed when compared to 2.44 to 1.6 in the placebo group. We also noticed a decrease of the number of hospitalizations and the number of transfusions which is less important in the group supplemented with spirulina. In conclusion, this study showed that supplementation in spirulina had a significant impact on children suffering from sickle cell anemia. This is even despite the fact that the difference between the two groups is not significant in some cases.

Objective: To report a case of Chronic Lymphoid Leukemia in a 28-year-old young subject, with variable clinical features and a TP53 mutation, diagnosed and followed up in the Onco-Hematology department of the HNN. Observation: 28-year-old patient, having consulted for polyadenopathy and physical asthenia, whose clinical examination found a conscious patient, submaxillary, laterocervical, axillary and inguinal lymphadenopathy, bilateral, symmetrical, painless and non-compressive whose largest measures 3 cm in diameter. Hepato-splenomegaly and epistaxis. Predominantly lymphocyte hyperleukocytosis, immunophenotyping revealed low CD19+, CD5+, CD23+, CD20 monoclonal B lymphoid proliferation. The Matutes score was 4. A karyotype showed a three-chromosome translocation; the short arm of a chromosome 2, the long arm of a chromosome 11 and the long arm of a chromosome 13, and a translocation between the long arm of a chromosome 6 and the long arm of a chromosome 18. A FISH objectified a led 17p. The diagnosis of Binet Stage C CLL with positive del 17p and complex karyotype was retained. Despite the poor prognosis, the R-C (Rituximab-Chlorambucil) protocol was instituted with once-weekly transfusions. The patient is still alive in partial clinical and biological remission. Conclusion: Despite therapeutic progress, the presence of the deletion of chromosome 17p with TP53 mutation and the young age of the patient does not change the patient's prognosis.

Von Willebrand's disease was first described in 1926 by Erik Von Willebrand. It is a genetic, constitutional defect of hemostasis that is different from hemophilia. It is classified among the rare diseases whose clinical manifestations are dominated by a hemorrhagic profile, which varies from patient to patient. It is an easily diagnosed disease based on a quantitative and qualitative bioassay of VWF. Treatment is multidisciplinary and is based on well-structured prevention. We report the first case of von Willebrand disease in Niger, diagnosed in the Hematology Department of Niamey's National Hospital.

No abstract